. 1
( 2 .)



>>

eOCaAieaeEau

aIUIEIOEI· O?E OOOIEIO?U?OOUE??
E OOO?EUE?AOIOI ?U?EUA:
IO‚?A OOIAIE?
O.a. cOOIO‚
oI.–IO??. eAac, O?OUAOOO?
Ei aIOUEUUU ?A‚IUOIO„EE eAac, aOOI‚

iiiaeeia?o?iiaoee (na?iiaaaoeaiua ii ?aaiaoieaiiio oaeoi?o) — a?oiia iaoiaaiaca ainiaeeoaeuiuo ?aaiaoe?aneeo caaieaaaiee, a oii ?enea niiiaeeia?o?eoa

N ainiaeeoaeuiuo ?aaiaoe?aneeo caaieaaaiee, i?aaiiei?eoaeuii eioaeoeii- [6] e IA [7]. Ii aaiiui yenia?eiaioaeuiuo enneaaiaaiee, o «o?ainaaiiuo» iuoae n ae-
iie yoeieiaee, ?acaeaa?ueony o aaiaoe?anee i?aa?aniiei?aiiuo eeo [1]. E iei io- ia?i?iaoeoeae OII–? ?acaeaaaony neia?ii, iaiiieia?uee AN o ?aeiaaea [8,9]. A nu-
iinyony aieeeice?o?uee niiiaeeeo (AN), ini?eaoe?aneee a?o?eo (IA), ?aaeoeaiua ai?ioeao iaoeaioia n AN ioia?aii oaaee?aiea eiioaio?aoee OII–? [10], a a e?anooi-

a?o?eou (?aA) (aee??ay neia?ii ?aeoa?a), yioa?iiaoe?aneea a?o?eou (i?e ianiaoe- ai–iiaacaioiuo ni?eaiaieyo aeia?yeni?anney e?IE e aaeea OII–? [11]. Oaaee?aiea
oe?aneii ycaaiiii eieeoa, aieacie E?iia, aieacie Oeiiea), ino?ue ia?aaiee oaa- eiioaio?aoee OII–? a neiiaeaeuiie ?eaeinoe iaia?o?aii i?e ?aaeoeaiuo a?o?eoao
eo, iaaeooa?aioe?iaaiiay niiiaeeia?o?iiaoey, iaeioi?ua a?oaea caaieaaaiey e [12], oioy neioac OII–? ia?eoa?e?aneeie eeioioeoaie ii?ao auou nie?ai, ?oi, eae

neia?iiu, ioa?aeoa?eciaaiiua iaiaa iia?iaii. n?eoa?o, i?aa?aniieaaaao e ia?nenoe?iaaie? aaeoa?eaeuiie eioaeoee [13]. A ei?a ia-
Iniiaaieai aey iauaaeiaiey yoeo caaieaaaiee a iaio a?oiio yaeyaony iaee- oeaioia n ini?eacii iaae?aaaony oaaee?aiea niaa??aiey OII–?, ?oi niinianoaoao
?ea eiiieaena iaueo eeeie?aneeo, yieaaieieiae?aneeo e aaiaoe?aneeo i?eciaeia: neioaco a?oaeo «i?iainiaeeoaeuiuo» iaaeaoi?ia e aiiioico ea?aoeiioeoia [14]. Eoeu-

• Nae?ieeaeo n (eee) aac niiiaeeeoa oeae?oaiua ia?eoa?e?aneea iiiioeou, auaaeaiiua ec e?iae iaoeaioia n ini?eaoe?a-
• Ia?eoa?e?aneee a?o?eo, yioaceo, aaeoeeeo neei a?o?eoii, niiioaiii neioace?o?o ecauoi?iia eiee?anoai OII–?, ii n?aaiaie? n
• Naycu n o?iie?aneei ainiaeaieai eeoa?ieea eeaoeaie cai?iauo aiii?ia [15]. OII–? aeoeae?oao oaeoi? o?aine?eioee NF–?B, ?oi

• Naycu n ini?eacii e a?oaeie oeiaie ii?a?aiey ei?e e neecenouo iaiei?ae i?eaiaeo e i?ieeoa?aoee neiiaeaeuiie oeaie, ia?aiauaie? eaeeioeoia a ciio ain-
• Naiaeiay i?aa?aniiei?aiiinou iaeaiey, neioaco a?oaeo «i?iainiaeeoaeuiuo» oeoieeiia e oneeaie? RANKL–caaene-
• Aianonoaaiua i?iyaeaiey: oaaeo, ea?aeo, ii?a?aiea ei?e e neecenouo iai- iiai inoaieeao?iaaiaca [15]. Oaaee?aiea eiioaio?aoee OII auyaeaii o iaoeaioia n

ei?ae. ino?ui oaaeoii e ei??aee?oao n ?eneii aai ?aoeaeae?iaaiey [16].
• Ionoonoaea ?aaiaoieaiiai oaeoi?a
Aieeeice?o?uee niiiaeeeo
• Naycu n HLA–B27.

Oa?iaeioa?aiey niiiaeeia?o?iiaoee oaeoe?anee iniiauaaaony aeaaiui ia?a-
cii ia neiioiiaoe?aneie oa?aiee ianoa?ieaiuie i?ioeaiainiaeeoaeuiuie i?aia?a- Aieeeice?o?uee niiiaeeeo (AN) — o?iie?aneia nenoaiiia ainiaeeoaeuiia
oaie (IIAI) e i?eiaiaiee oeceioa?aiaaoe?aneeo iaoiaia [2,4]. Yooaeoeaiinou yoeo caaieaaaiea, i?eaiayuaa e i?aeiouanoaaiiiio ii?a?aie? e?anooiai–iiaacaio-

iaoiaia, a oae?a iaeioi?uo aaceniuo i?ioeaiainiaeeoaeuiuo i?aia?aoia (AIAI), n iuo ni?eaiaiee e iicaiii?ieea. Auaaey?o ia?ae?io? (eaeiiaoe?aneo?) e aoi?e?-
oniaoii i?eiaiyaiuo i?e ?aaiaoieaiii a?o?eoa (?A), a ioiioaiee caiaaeaiey i?i- io? (naycaiio? n ?aaeoeaiuie a?o?eoaie, ini?eacii eee ainiaeeoaeuiuie caaiea-
a?anne?iaaiey aieeeice?iaaiey iicaiii?ieea e e?anooiai–iiaacaioiuo ni?eaiaiee, aaieyie eeoa?ieea) oi?iu caaieaaaiey. Caaieaaaiea aicieeaao n ?anoioie io 0,4
i?e niiiaeeia?o?iiaoeyo ia aieacaia [2,3]. ai 1,4%, ?aua a iia?inoeiaii eee iieiaii aic?anoa, e?aeia ?aaei iinea 45 eao.

Ia?niaeoeaiia iai?aaeaiea oa?iaeioa?aiee niiiaeeia?o?iiaoee naycaii n Io??eiu caaieaaa?o a 3 ?aca ?aua, ?ai ?aiueiu. Aey AN oa?aeoa?ii oy?aeia ia-

i?eiaiaieai aeieiae?aneeo aaaioia, a ia?ao? i?a?aau iiiieeiiaeuiuo aioeoae, e oa- ?ooaiea ooieoee nonoaaia, aaaouaa e eiaaeeaiinoe a oa?aiea 10 eao aieacie [17].
eoi?o iae?ica iiooiee (OII–?) [2,5]. Iaiiiiei, ?oi OII–? i?iyaeyao iiiai?eneaiiua E ni?aeaie?, aeaaiic ia?aaei noaaeony i?aiu iicaii – a n?aaiai ?a?ac 10–15 eao

«i?iainiaeeoaeuiua» yooaeou, eioi?ua eia?o ooiaaiaioaeuiia cia?aiea a eiioii- io ia?aea caaieaaaiey.

Oaaeeoa 1. Yooaeoeaiinou eioeeeneiaaa i?e niiiaeeia?o?iiaoeyo
/
Ioe?uoia, 25 iaoeaioia Iauay ioaiea yooaeoeaiinoe (AAO – 100 ii):
Temekonidis [22] 1 aia, 5 ia/ea
c AC (ana HLA–B27+) >20%–92%, >50%–84%, >70%–52%.
?a?ac 1 aia BASDAI 50%–57,1%, ASAS 20 –71,4%,
ASAS 40 – 65,7%, ASA 5/6 – 51,4% ?a?ac 2 aiaa
Nikas [29] Ioe?uoia, 35 n AN 2 aiaa, 5 ia/ea
BASDAI 50% – 31,4%, ASAS 20–40%, ASAS 40 – 31,4%,
ASAS 5/6 – 25,7% ?a?ac 2 aiaa ea?aiea auei yooaeoeaii o 89%
12 iaa. ?EE +
?EE, n io?uoie oacie BASDAI 50% o 53% vs 8% ieaoaai,
Braun [23] 48 ioe?uoay oaca/
70 iaoeaioia ainoiaa?iia oeo?oaiea eiaaenia BASFI, BASMI
5 ia/ea
Yooaeo nio?aiyaony a oa?aiea aiaa oa?aiee:
Braun [27] Ioe?uoay oaca 1 aia (54 iaa.)
BASDAI 50% – 63% iaoeaioia
Ioe?uoay oaca Yooaeo nio?aiyaony a oa?aiea 2–o eao oa?aiee:
Braun [28] 2 aiaa (102 iaa.)
52 iaoeaioa BASDAI 50% – 58% iaoeaioia
ASAS 20 – eioeeeneiaa 61,2% vs ieaoaai 19,2% (?<0,001).
?EE (ASSERT),
ASAS 40 – eioeeneiaa 49% vs ieaoaai 12% (p<0,001)
Van der Heijde 201 iaoeaio iieo?ae
24 iaa./5 ia/ea ASAS ?aienney – eioeeeneiaa 22,4% vs ieaoaai 1,3% (p<0,001)
[31] eioeeeneiaa,
BASDAI 50% – eioeeeneiaa 51% vs ieaoaai 10,7% (p<0,001)
71 – ieaoaai
BASFI>2 – eioeeeneiaa 47,5% vs ieaoaai 13,3% (p<0,001)
Ioe?uoia, 24 iaoeaioa Iiei?eoaeuiay aeiaieea aano?iyioa?ieiae?aneeo i?iyaeaiee
Generini [76] n aieaciu? E?iia 12–18 ian./5 ia/ea (p<0,001), BASDI (p<0,01), iuoa?ii–neaeaoiuo aieae (p<0,01),
e niiiaeeia?o?iiaoeae ia?eoa?e?aneiai a?o?eoa (p<0,01), yioaceoia (p<0,01)

528 13, 8, 2005
Yooaeoeaiinou eioeeeneiaaa i?e AN oaaaeoaeuii i?iaaiiino?e?iaaia iiiaeie enneaaiaaoaeyie [18–31] (oaae. 1). Ia?aia ioe?uoia eniuoaiea eioeeeneiaaa
o iaoeiaoia n AN auei i?iaaaaii a 2000 a. Auei onoaiiaeaii, ?oi eioeeeneiaa a aica 5 ia/ea aucuaaao nouanoaaiiia oeo?oaiea (>50% ii eiaaeno BASDAI) o 9 ec 10 iaoe-

aioia n oy?aeui AN [18,19]. Oae eae iaino?aiea caaieaaaiey eiaei ianoi ?a?ac 6–12 iaa. iinea eioocee, a i?ioanna iineaao?ueo enneaaiaaiee eioa?aae ia?ao eiooceyie
ninoaaee 6 iaa. [23]. I?eioeieaeuiia cia?aiea eiaao oio oaeo, ?oi o aieuoeinoaa iaoeaioia yooaeoeaiinou oa?aiee nio?aiyaony a oa?aiea aeeoaeuiiai a?aiaie (aieaa 3–o

eao iaae?aaiey) [25], a ioee?ea io aieacie E?iia, i?e eioi?ie iaae?aaaony nie?aiea yooaeoeaiinoe o iaoeaioia, eioi?ua iieo?aee eioocee eioeeeneiaaa ?a?ac ia?aaii-
ia?iua i?iia?ooee a?aiaie [34]. Ia oiia ea?aiey ioia?aii oeo?oaiea niiniaiinoe e o?oaiaie aayoaeuiinoe [32]. Ii aaiiui iaaieoii–?aciiainiie oiiia?aoee (I?O) [33]
e noeioea?aoee [20] ea?aiea eioeeeneiaaii i?eaiaeo e oiaiuoaie? i?eciaeia ainiaeaiey a iicaiii?ieea e e?anooiai–iiaacaioiuo ni?eaiaieyo. Iiaiaiie aeiaieee ain-

iaeaiey a yoeo o?anoeao neaeaoa ia auei i?iaaiiino?e?iaaii ia oiia ea?aiey a?oaeie i?aia?aoaie, eniieuco?ueieny i?e niiiaeeia?o?iiaoeyo. Oioy eciaiaiee a ciia ai-
eeeice?iaaiey ia oiia ea?aiey eioeeeneiaaii ia ioia?aii, a iinea caaa?oaiey ea?aiey o iiiaeo iaoeaioia a oa?aiea 12–36 iaa. ?acaeaaaony iaino?aiea [61], i?e ainoe-
?aiee iieiie (eee ?anoe?iie) ?aiennee (e ii?iaeecaoee eiioaio?aoee N?A), iaino?aiea ?acaeaaaony iic?a [35], a aiciaiiaeaiea oa?aiee eioeeeneiaaii o iiaaaey?uaai

aieuoeinoaa iaoeaioia iicaieyao eoie?iaaou iaino?aiea.
I?aaaa?eoaeuiua ?acoeuoaou naeaaoaeunoao?o i oii, ?oi eioeeeneiaa ieacuaaao iiei?eoaeuiia aaenoaea ia a?oaea i?iyaeaiey eiioiiiaoieiae?aneiai i?ioanna i?e
AN. Iai?eia?, eia?ony aaiiua, ?oi o iaoeaioia n AN iaae?aaaony nie?aiea ieia?aeuiie ieioiinoe einoiie oeaie (IIEO), ?oi annioee?oaony n oaaee?aieai ?enea ?acae-

oey ia?aeiiia einoae neaeaoa [36–38]. I?aaaa?eoaeuiua aaiiua naeaaoaeunoao?o ia oaaee?aiee IIEO o iaoeaioia AN ia oiia ea?aiey eioeeeneiaaii [39,40], oioy
i?eaiaeo ee yoi e nie?aie? ?enea ia?aeiiia – ia ecaanoii. A?oaie aniaeo yoie i?iaeaiu naycai n iiceoeaiui aeeyieai eioeeeneiaaa ia ea?aeiaaneoey?iua oaeoi?u ?e-
nea, a ?anoiinoe, ?acenoaioiinou e einoeeio, eioi?ay ii?ao auou naycaia n aeia?i?iaoeoeae OII–? [41]. Eia?ony aaiiua, ?oi aaaaaiea eioeeeneiaaa i?eaiaeo e nie?a-

ie? ?acenoaioiinoe e einoeeio o iaoeaioia n ?A e AN [42].
Iaaaaii Ia?aoia?iaiay ?aai?ay a?oiia ii ioaiea aieeeice?o?uaai niiiaeeeoa (Assessment in Ankylosing Spondilitis – ASAS) [43,44] e Aia?eeaineay annioeaoey ii
eco?aie? niiiaeeeoa (Spondylitis Association of America – SAA) [45] ?ac?aaioaee ?aeiiaiaaoee ii i?eiaiaie? e ioaiea yooaeoeaiinoe eioeeeneiaaa i?e AN, eioi?ua i?aa-

noaaeaiu a iaoae i?aauaouae ioaeeeaoee [46].


Ini?eaoe?aneee a?o?eo



Ini?eaoe?aneee a?o?eo (IA) – o?iie?aneay ainiaeeoaeuiay a?o?iiaoey, ?ani?ino?aiaiiinou eioi?iai a iiioeyoee eieaaeaony io 0,1 ai 1%. Ini?eac ii?a?aao 1–3%
ianaeaiey caiiiai oa?a, i?e?ai o o?aoe iaoeaioia ?acaeaaaony IA. Oy?aeia ii?a?aiea nonoaaia, oa?aeoa?eco?uaany auno?ui i?ia?anne?iaaieai o?a a ia?aua aiau io

ia?aea aieacie, ?acaeaaaony o 40–60% iaoeaioia n IA [47,48].
Eioeeeneiaa ca?aeiiaiaiaae naay eae ??acau?aeii ia?niaeoeaiue i?aia?ao aey ea?aiey eae ini?eaca [49,50], oae e IA [30,51–57] (oaae. 2). A neaa ca ?aaeno?aoeae
IA a no?aiao Aa?iiaeneiai Ni?ca iaaaaii yoi iieacaiea auei ca?aaano?e?iaaii e a ?innee. Oioy IA iiea ia yaeyaony ioeoeaeuiui iieacaieai aey iacia?aiey eioeee-

neiaaa, ia aucuaaao niiiaiey, ?oi yoi i?iecieaao a aee?aeoaa a?aiy. Iaaaaii Annioeaoey ?aaiaoieiaia Aaeeeia?eoaiee i?aanoaaeea eeeie?aneea ?aeiiaiaaoee, eana-
?ueany i?eiaiaiey aeieiae?aneeo aaaioia, aee??ay eioeeeneiaa i?e IA [58].



A?oaea niiiaeeia?o?iiaoee


I?aaaa?eoaeuiua ?acoeuoaou naeaaoaeunoao?o ia yooaeoeaiinoe eioeeeneiaaa i?e iaaeooa?aioe?iaaiiii niiiaeeia?o?eoa [39,59]. A iaiii enneaaiaaiee, a eioi?ia
auei aee??aii 6 iaoeaioia n oy?aeui iaaeooa?aioe?iaaiiui niiiaeeia?o?eoii, auei iieacaii, ?oi ia oiia aaaaaiey i?aia?aoa (3–5 ia/ea) ioia?aaony i?aiu auno?ay iiei-

?eoaeuiay aeiaieea neiioiiia ii?a?aiey iicaiii?ieea e ia?eoa?e?aneeo nonoaaia, ei??aee?o?uay ni nie?aieai aeoeaiinoe ainiaeaiey [59]. Iienaii aaa iaoeaioa n ?aae-

oeaiui a?o?eoii, naycaiiui n ea?neieicii, o eioi?uo ia oiia ea?aiey eioeeeneiaaii ioia?ai auno?ue eeeieei–eaai?aoi?iue yooaeo [60]. I?aanoaaeyao ii?aaaeaiiue ei-
oa?an eeeie?aneia iaae?aaiea ia oniaoiii i?eiaiaiee eioeeeneiaaa o AE?–iiceoeaiiai iaoeaioa n neia?iiii ?aeoa?a. [61]. Iiyaeeenu niiauaiey i niiniaiinoe eioeeene-

iaaa eoie?iaaou i?iyaeaiey aieeieaiie yioa?iiaoee [62], yioaceoia [84,85] e oaaeoa [63–65], ii?a?aiey ei?e i?e neia?iia SAPHO [86]. I?aaaa?eoaeuiua ?acoeuoaou naeaaoaeu-
noao?o ia yooaeoeaiinoe eieaeuiiai aaaaaiey eioeeeneiaaa a iaeanou e?anooiai–iiaacaioiuo ni?eaiaiee [87].
Niiiaeeia?o?iiaoey – iaii ec naiuo ?anouo aiaeeoa?iuo inei?iaiee ainiaeeoaeuiuo caaieaaaiee eeoa?ieea, a ia?ao? i?a?aau aieacie E?iia [66–68]. I?e yoii

oneiaii auaaey?o 3 oeia nonoaaiie iaoieiaee: oei I – ia?eoa?e?aneee iaooea?oeeoey?iue a?o?eo; oei II – ia?eoa?e?aneee ianeiiao?e?iue iieea?o?eo; oei III – na?iiaaa-
oeaiue niiiaeeia?o?eo, eiiaaa n ii?a?aieai ia?eoa?e?aneeo nonoaaia [67]. Ia?yao n ii?a?aieai nonoaaia oa?aeoa?ii ?acaeoea yioaceoia, oaiineiiaeoa, aaeoeeeoa [68].
Aunieay yooaeoeaiinou eioeeeneiaaa i?e aieacie E?iia i?iaaiiino?e?iaaia i?aiu iiiaeie enneaaiaaoaeyie [69–73]. Ii aaiiui ?yaa aaoi?ia, ea?aiea eioeeneiaaii

i?eaiaeo e eoie?iaaie? nonoaaiuo i?iyaeaiee i?e aieacie E?iia [74–76] (oaae. 1).


Iaoaieci aaenoaeye



Iaoaieci aaenoaey eioeeeneiaaa i?e niiiaeeia?o?iiaoeyo e IA ai eiioa ia ynai. Ii aaiiui D. Baeten e niaao. [77], i?e AN ia oiia ea?aiey eioeeeneiaaii iaae?aa-
aony oaaee?aiea neioaca eioa?oa?iia (EOI)–? e nie?aiea EE–10, ?oi, ii iiaie? aaoi?ia, io?a?aao niiniaiinou eioeeeneiaaa ainnoaiaaeeaaou Th1 oei eiioiiiai ioaaoa. A

a?oaii enneaaiaaiee auei iieacaii, ?oi aaaaaiea eioeeeneiaaa i?eaiaeo e nouanoaaiiiio nie?aie? neioaca EOI–? e OII–? O–eeioioeoaie [78]. Ainoiaa?iie aeiaieee
a?oaeo «i?iainiaeeoaeuiuo» e «aioeainiaeeoaeuiuo» oeoieeiia, aee??ay EE–1, EE–10, o?ainoi?ie?o?uee oaeoi? ?inoa (OO?–?) e EOI–?, ia oiia ea?aiey eioeeeneiaaii
ia ioia?aii.

I?e na?eeiii ii?oieiae?aneii enneaaiaaiee ioia?aii, ?oi ia oiia ea?aiey eioeeeneiaaii o iaoeaioia n AN iaae?aaaony oiaiuoaiea oieueiu neiiaeaeuiie iai-
ei?ee e nie?aiea ?enea CD55+ neiiaeioeoia, iaeo?ioeeia e CD68+ e CD163+ iae?ioaaia, yeni?annee ninoaenoie eeaoi?iie iieaeoeu aaaacee (VCAM–1) ia yiaioaeeaeu-
iuo eeaoeao. ?enei eeioioeoia (CD20+) e ieaciaoe?aneeo eeaoie ia iaiyeinu [79]. O iaoeaioia n IA, iieo?aaoeo eioeeeneiaa, iaia?o?aii nie?aiea eiee?anoaa iae?i-

oaaia, CD31+ eeaoie, e ninoaia, yeni?anne?o?ueo ninoaenoue yiaioaeeaeuiue oaeoi? ?inoa e a?oaea ia?ea?u aiaeiaaiaca [80].


I?iaiice?iaaiea yooaeoeaiinoe



Eia?ony aaiiua i oii, ?oi o iaoeaioia, ioaa?a?ueo ia ea?aiea eioeeeneiaaii, enoiaiue o?iaaiu N?A e OII–? auoa, ?ai o iaoeaioia, ia ioaa?a?ueo ia ea?aiea
eOCaAieaeEau
IFN–gamma) in ankylosing spondylitis: a close correlation between serum IL–6 and disease activity and severity. Br J Rheumatol
yoei i?aia?aoii [23,81]. Ia enee??aii, ?oi o iaoeaioia n enoiaii ieceei o?iaiai 1994; 33(10):927–31
OII–? ?acaeoea caaieaaaiey iaoiaaiaoe?anee a aieuoae noaiaie naycaii n 11. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization tech-

niques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;
«OII–? iacaaeneiuie» iaoaieciaie. Eia?ony aaiiua i oii, ?oi yooaeoeaiinou
38(4): 499–505.
ea?aiey eioeeeneiaaii auoa o iaoeaioia n iaiuoae aeeoaeuiinou? caaieaaaiey
12. Ribbens C, Andre B, Kaye O et al. Increased synovial fluid levels of interleukin–12, sCD25 and sTNF–RII/sTNF–RI ratio
[31,82], aieaa ieceeie cia?aieyie eiaaena BASFI, iieiaiai aic?anoa e n oaaee?a-
delineate a cytokine pattern characteristic of immune arthropathies. Eur Cytokine Netw 2000; 11:669–76.
ieai NIY e N?A [82], a oae?a o oao, o eioi?uo i?e I?O auyaey?ony i?eciaee ainia- 13. Braun J, Yin Z, Spiller I, Siegert S et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines,
eaiey e?anooiai–iiaacaioiuo ni?eaiaiee [83]. Iaiaei nouanoao?uea «i?aaeeoi- by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum 1999; 42:2039–44.

14. Victor FC, Gottlieb AB. TNF– and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs
?u» yooaeoeaiinoe iaeaaa?o iaainoaoi?iie ?oanoaeoaeuiinou?. Iai?eia?, oi?i-
Dermatol 2002;1: 264–75.
oee «ioaao» ia eioeeeneiaa eiae ianoi o 70% iaoeaioia n aunieei o?iaiai N?A
15. Ritchlin CT, Haas–Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF–? and RANKL–mediated osteoclastoge-
e o 30% iaoeaioia n ii?iaeuiui o?iaiai N?A.
nesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111:821–31.
Oaeei ia?acii, eioeeeneiaa – ia?niaeoeaiue i?aia?ao aey ea?aiey i?aeoe- 16. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM et al. Aqueous humor and serum tumor necrosis factor– in
?anee anao iniiaiuo oi?i niiiaeeia?o?iiaoee e IA o iaoeaioia, ?acenoaioiuo e clinical uveitis. Ophthalmic Res 2001; 33:251–5.

17. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997; 36(7):
oa?aiee IIAI e AIAI. A aaeuiaeoeo enneaaiaaieyo iaiaoiaeii iieo?eou ioaaou
766–71.
ia neaao?uea aii?inu:
18. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondyli-
• Iicaieeo ee ?aiiyy aeaaiinoeea e iacia?aiea eioeeeneiaaa a aaa?oa ai-
tis with the antitumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43(6): 1346–52.
eacie oeo?oeou ioaaeaiiue i?iaiic i?e niiiaeeia?o?iiaoeyo? 19. Brandt J, Haibel H, Sieper J, Reddig J, Braun J. Infliximab treatment of severe ankylosing spondylitis: one–year followup.
• Eae aieai iaoeaiou aie?iu iieo?aou oa?aie? eioeeeneiaaii? Arthritis Rheum 2001; 44(12):2936–7.
20. Hadi A, Hickling P, Brown M, Al Nahhas A. Scintigraphic evidence of effect of infliximab on disease activity in ankylos-
• Eaeea eeeie?aneea, eaai?aoi?iua e eino?oiaioaeuiua iaoiau iaeaieaa iioe-
ing spondylitis. Rheumatology (Oxford) 2002; 41(1):114–6.
iaeuiu aey ioaiee e i?iaiice?iaaiey yooaeoeaiinoe oa?aiee eioeeeneiaaii?
21. Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E, et al. Efficacy of infliximab in refracto-
aEUA?UU?
ry ankylosing spondylitis: results of a six–month open–label study. Rheumatology (Oxford) 2002;41(11):1280–5.
1. Khan MA Update on spondyloarthropathies Ann Intern Med 2002; 136:896–907
22. Temekonidis TI, Alamanos Y, Nikas SN, Bougias DV, Georgiadis AN, Voulgari PV, et al. Infliximab therapy in patients with
2. Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment,
ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003; 62(12):1218–20.
anti–TNF–alpha therapy and other novel approaches. Arthritis Res 2002; 4(5):307–21.
23. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab:
3. Dougados M, van der Linden S, Leirisalo–Repo M, et al. Sulphasalazine in the treatment of spondyloarthropathy; a ran-
a randomised controlled multicentre trial. Lancet 2002; 359:1187–93.
domized multicenter, double–blind–controlled study. Arthritis Rheum 1995; 38: 618–627.
24. Brandt J, Listing J, Alten R, Burmester G, Gromnica–Ihle E, Schneider M, et al. One year results of a double–blind place-
4. Wanders A, van der Heijde D, Landewe R, et al. Inhibition of radiographic progression in ankylosing spondilitis (AS) by
bo controlled, phase III clinical trial of infliximab in active ankylosing spondylitis [abstract]. Arthritis Rheum 2002;
continuous use of NSAIDs. Arthritis Rheum 2003; 48 (Suppl 9): S233
46(Suppl.): S429, Abstract 1122.
5. Davis JC. Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. Semin Arthritis Rheum
25. Baraliakos X, Brandt J, Listing J, Rudwaleit M, Sieper J, Braun J. Clinical response to long–term therapy with infliximab
2004; 34: 668–677
in patients with ankylosing spondylitis–results after 3 years [abstract]. Presented at: Annual European Congress of
6. Keller C, Webb A, Davis J. Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a
Rheumatology; Berlin Germany; June 9–12, 2004. Abstract SAT0084.
brief report and literature review. Ann Rheum Dis 2003; 62: 1128–1132.
26. Maksymowych W, Jhangri G, Lambert R et al. Infliximab in ankylosing spondylitis: a prospective observational inception
7. Veale DJ, Ritchin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64: 26–29
cohort analysis of efficacy and safety. J Rheumatol 2002; 29: 959–965
8. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour
27. Braun J, Brandt J, Listing J, et al. Long–term efficacy and safety of infliximab in the treatment of ankylosing spondilitis:
necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10(13):4025–31.
an open, observational, extension study of a three–month, randomized, placebo–controlled trial. Arthritis Rheum 2003; 48:
9. Crew MD, Effros RB, Walford RL, Zeller E, Cheroutre H, Brahn E. Transgenic mice expressing a truncated Peromyscus leu-
1187–1193.
copus TNFalpha gene manifest an arthritis resembling ankylosing spondylitis. J Interferon Cytokine Res 1998; 18(4):219–25.
28. Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety on infliximab in the treatment of anky-
10. Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J, et al. Serum cytokines (IL–6, TNF–alpha, IL–1 beta and


Oaaeeoa 2. Yooaeoeaiinou eioeeeneiaaa i?e ini?eaoe?aneii a?o?eoa
/n /
ACR 20–10 iaoeaioia (2 iaa.)
Antoni [52] Ioe?uoia, 10 iaoeaioia 54 iaa., 5 ia/ea ACR 50–8 iaoeaioia (10 iaa.)
ACR 70–6 iaoeaioia (54 iaa.)
ACR 20–9 iaoeaioia
Ioe?uoia, 16 iaoeaioia ACR 50–8 iaoeaioia
Salvarini [53] 30 iaa., 3 ia/ea
(noaaeeuiay aica IO) ACR 70–8 iaoeaioia
Oeo?oaiea eiaaena PASI – 83%
Nonoaaiie n?ao – iao yooaeoa
N?ao i?eiooeinoe nonoaaia – oeo?oaiea (p<0,01)
Eiaaen PASI – oeo?oaiea (p<0,002)
Feletar [54] Ioe?uoia, 16 iaoeaioia 54 iaa., 5 ia/ea
HAQ – oeo?oaiea (p=0,02)

. 1
( 2 .)



>>